MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
126.75
+2.08
+1.66%
Opening 15:25 11/18 EST
OPEN
124.54
PREV CLOSE
124.67
HIGH
127.51
LOW
124.11
VOLUME
254.05K
TURNOVER
--
52 WEEK HIGH
160.81
52 WEEK LOW
77.00
MARKET CAP
8.27B
P/E (TTM)
26.85
1D
5D
1M
3M
1Y
5Y
1D
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 37.6%
NASDAQ · 2d ago
Weekly Report: what happened at PTGX last week (1109-1113)?
Weekly Report · 2d ago
BMO Maintains Buy Rating and $190 Price Target on Protagonist Therapeutics, Citing Icotyde Potential and Pipeline Catalysts
TipRanks · 11/10 18:06
Analysts Offer Insights on Healthcare Companies: McKesson (MCK) and Protagonist Therapeutics (PTGX)
TipRanks · 11/10 15:00
Analysts Offer Insights on Healthcare Companies: InMed Pharmaceuticals (INM), Protagonist Therapeutics (PTGX) and Johnson & Johnson (JNJ)
TipRanks · 11/10 08:00
Weekly Report: what happened at PTGX last week (1102-1106)?
Weekly Report · 11/09 10:08
J&J posts late-stage trial win for plaque psoriasis pill in psoriatic arthritis
Seeking Alpha · 11/07 15:40
Protagonist Therapeutics Price Target Raised to $221.00/Share From $170.00 by HC Wainwright & Co.
Dow Jones · 11/06 20:23
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.